Skip to main content
OpenTrials
Completed

NCT Number: NCT00765024

Ivermectin Versus Albendazole for Chronic Strongyloidiasis

A prospective controlled trial to compare the efficacy and safety of 7-day albendazole, single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Strongyloidiasis Helminthiasis Infections Nematode Infections Parasitic Diseases Rhabditida Infections Secernentea Infections Strongyloidiasis

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Siriraj Hospital

Bangkoknoi, Bangkok, 10700, Thailand

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with positive strongyloides larva in the stool

Exclusion criteria

  • Pregnancy
  • Lactating women
  • Known allergy to any study drug

Treatment and study plan

Ivermectin

Drug

single dose of 200 mcg/kg

Other names: stromectal

Albendazole

Drug

Albendazole 7 days

Primary outcomes

  1. cure rate

    Time frame: 1 year

Secondary outcomes

  1. safety

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Mahidol University

Other

Collaborators

  • Atlantic Laboratory Ltd

Registry information

Official study title

Efficacy and Safety of Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Oct 2, 2008
Registry last updated
Sep 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.